2009.09.03 Weekly Broadcast Email
The following updates were made to the website for the week of August 31, 2009.
The following adverse events were reported during the month of August. A PDF of the AE document has been attached to this email and a summary of the event can be found on the adverse event page of the website.
97202: 52, 53
97405: 6, 7
Accrual Totals for August:
In the month of August, 9 patients were accrued to CCCWFU CCOP Research Base trials. SCCC and Wake Forest were tied for the top accruing site. See the Research Base home page for further information.
2009 Annual Meeting Registration
The Research Base 9th Annual Meeting will be held on September 24-26, 2009 at the Renaissance Hotel in Asheville, NC. Once again the fall foliage of the Blue Ridge Parkway and downtown Asheville will provide the backdrop of our meeting. Thursday afternoon offers the attendee an opportunity for a hands-on workshop with the new Research Website as well as appointments for certification for the Donepezil Trial. The meeting will open with a presentation from Betty Ferrell, PhD, followed by round tables, an open forum discussion on proposed research base concepts, presentations on recruitment and retention issues, and communication with cancer patients. The reception will be held on the “Top of the Plaza” which is located on the top floor of the Renaissance Hotel and affords spectacular views all around. Saturday morning will open with a presentation from Dr. Jeff White, Director of the Office of Complimentary Alternative Medicine. The meeting will close with reviews of open protocols as well as protocols in development. Registration is now open and can be faxed, emailed, or submitted online by September 11. All information regarding the annual meeting can be found by visiting our website at www.wfubmc.edu/cancer/researchbase/Annual+Meeting. Contact Lisa Hawkins at (336) 716-0891 or email@example.com if you have any questions. See you in Asheville!
Featured Study: Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients
Have you considered opening 91105 at your site? Has your site accrued patients to this study recently? You might be interested to know…
Several recent protocol changes have been made to study 91105, Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients. These changes were made to facilitate and simplify enrollment which include:
-Adding a $40 gift for participating
-Simplifying and reducing medication exclusions
Visit the recently updated 91105 webpage to view:
- Letter from the PI, Dr. Steve Rapp
- Brochure outlining recent changes
- Training video
97106 (Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors)only has 12 minority accrual slots open for patient accruals. We would like to see this study close by the end of the summer, so if you have patients that may be eligible for this study, please try and get them registered by then.
Wake Forest University Baptist Medical Center
Department of Radiation Oncology
Research Base Protocol Information Office
2000 West First Street, Suite 401
Winston-Salem, NC 27104
Pager: 336-716-2440, ID number 1689
"It is better to fail in originality than to succeed in imitation."